| Year |
Citation |
Score |
| 2023 |
Galan A, Papaluca A, Nejatie A, Matanes E, Brahimi F, Tong W, Hachim IY, Yasmeen A, Carmona E, Klein KO, Billes S, Dawod AE, Gawande P, Jeter AM, Mes-Masson AM, ... ... Saragovi HU, et al. GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer. Frontiers in Oncology. 13: 1134763. PMID 37124505 DOI: 10.3389/fonc.2023.1134763 |
0.44 |
|
| 2021 |
Brahimi F, Galan A, Siegel S, Szobota S, Sarumic MV, Foster AC, Saragovi HU. . Molecular Pharmacology. PMID 34470776 DOI: 10.1124/molpharm.121.000301 |
0.453 |
|
| 2020 |
Brahimi F, Galan A, Jmaeff S, Barcelona PF, De Jay N, Dejgaard K, Young JC, Kleinman CL, Thomas DY, Saragovi HU. Alternative Splicing of a Receptor Intracellular Domain Yields Different Ectodomain Conformations, Enabling Isoform-Selective Functional Ligands. Iscience. 23: 101447. PMID 32829283 DOI: 10.1016/J.Isci.2020.101447 |
0.496 |
|
| 2020 |
Mossa AH, Galan A, Cammisotto PG, Velasquez Flores M, Shamout S, Barcelona P, Saragovi HU, Campeau L. Antagonism of proNGF or its receptor p75 reverses remodelling and improves bladder function in a mouse model of diabetic voiding dysfunction. Diabetologia. PMID 32699962 DOI: 10.1007/S00125-020-05222-4 |
0.416 |
|
| 2020 |
Jmaeff S, Sidorova Y, Lippiatt H, Barcelona PF, Nedev H, Saragovi LM, Hancock MA, Saarma M, Saragovi HU. Small-molecule ligands that bind the RET receptor activate neuroprotective signals independent of but modulated by co-receptor GFRα1. Molecular Pharmacology. PMID 32362584 DOI: 10.1124/Mol.119.118950 |
0.556 |
|
| 2020 |
Jmaeff S, Sidorova Y, Nedev H, Saarma M, Saragovi HU. Small-molecule agonists of the RET receptor tyrosine kinase activate biased trophic signals that are influenced by the presence of GFRa1 co-receptors. The Journal of Biological Chemistry. 295: 6532-6542. PMID 32245892 DOI: 10.1074/Jbc.Ra119.011802 |
0.46 |
|
| 2019 |
Szobota S, Mathur PD, Siegel S, Black K, Saragovi HU, Foster AC. BDNF, NT-3 and Trk receptor agonist monoclonal antibodies promote neuron survival, neurite extension, and synapse restoration in rat cochlea ex vivo models relevant for hidden hearing loss. Plos One. 14: e0224022. PMID 31671109 DOI: 10.1371/Journal.Pone.0224022 |
0.33 |
|
| 2019 |
Saragovi HU, Galan A, Levin LA. Neuroprotection: Pro-survival and Anti-neurotoxic Mechanisms as Therapeutic Strategies in Neurodegeneration. Frontiers in Cellular Neuroscience. 13: 231. PMID 31244606 DOI: 10.3389/fncel.2019.00231 |
0.36 |
|
| 2019 |
Tong W, Maira M, Roychoudhury R, Galan A, Brahimi F, Gilbert M, Cunningham AM, Josephy S, Pirvulescu I, Moffett S, Saragovi HU. Vaccination with Tumor-Ganglioside Glycomimetics Activates a Selective Immunity that Affords Cancer Therapy. Cell Chemical Biology. PMID 31105061 DOI: 10.1016/J.Chembiol.2019.03.018 |
0.53 |
|
| 2017 |
Galán A, Jmaeff S, Barcelona PF, Brahimi F, Sarunic MV, Saragovi HU. In retinitis pigmentosa TrkC.T1-dependent vectorial Erk activity upregulates glial TNF-α, causing selective neuronal death. Cell Death & Disease. 8: 3222. PMID 29242588 DOI: 10.1038/S41419-017-0074-8 |
0.302 |
|
| 2017 |
Platón-Corchado M, Barcelona PF, Jmaeff S, Marchena M, Hernández-Pinto AM, Hernández-Sánchez C, Saragovi HU, de la Rosa EJ. p75(NTR) antagonists attenuate photoreceptor cell loss in murine models of retinitis pigmentosa. Cell Death & Disease. 8: e2922. PMID 28703796 DOI: 10.1038/Cddis.2017.306 |
0.326 |
|
| 2017 |
Wu CL, Hardy S, Aubry I, Landry M, Haggarty A, Saragovi HU, Tremblay ML. Identification of function-regulating antibodies targeting the receptor protein tyrosine phosphatase sigma ectodomain. Plos One. 12: e0178489. PMID 28558026 DOI: 10.1371/journal.pone.0178489 |
0.314 |
|
| 2016 |
Brahimi F, Maira M, Barcelona PF, Galan A, Aboulkassim T, Teske K, Rogers ML, Bertram L, Wang J, Yousefi M, Rush R, Fabian M, Cashman N, Saragovi HU. The Paradoxical Signals of Two TrkC Receptor Isoforms Supports a Rationale for Novel Therapeutic Strategies in ALS. Plos One. 11: e0162307. PMID 27695040 DOI: 10.1371/Journal.Pone.0162307 |
0.331 |
|
| 2016 |
Barcelona PF, Sitaras N, Galan A, Esquiva G, Jmaeff S, Jian Y, Sarunic MV, Cuenca N, Sapieha P, Saragovi HU. p75NTR and Its Ligand ProNGF Activate Paracrine Mechanisms Etiological to the Vascular, Inflammatory, and Neurodegenerative Pathologies of Diabetic Retinopathy. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 36: 8826-41. PMID 27559166 DOI: 10.1523/Jneurosci.4278-15.2016 |
0.361 |
|
| 2016 |
Josephy-Hernandez S, Jmaeff S, Pirvulescu I, Aboulkassim T, Saragovi HU. Neurotrophin receptor agonists and antagonists as therapeutic agents: An evolving paradigm. Neurobiology of Disease. 97: 139-155. PMID 27546056 DOI: 10.1016/J.Nbd.2016.08.004 |
0.415 |
|
| 2015 |
Tong W, Maira M, Gagnon M, Saragovi HU. Ligands Binding to Cell Surface Ganglioside GD2 Cause Src-Dependent Activation of N-Methyl-D-Aspartate Receptor Signaling and Changes in Cellular Morphology. Plos One. 10: e0134255. PMID 26252487 DOI: 10.1371/journal.pone.0134255 |
0.63 |
|
| 2015 |
Barcelona PF, Saragovi HU. A Pro-Nerve Growth Factor (proNGF) and NGF Binding Protein, α2-Macroglobulin, Differentially Regulates p75 and TrkA Receptors and Is Relevant to Neurodegeneration Ex Vivo and In Vivo. Molecular and Cellular Biology. 35: 3396-408. PMID 26217017 DOI: 10.1128/Mcb.00544-15 |
0.555 |
|
| 2015 |
Goupil E, Fillion D, Clément S, Luo X, Devost D, Sleno R, Pétrin D, Saragovi HU, Thorin É, Laporte SA, Hébert TE. Angiotensin II type I and prostaglandin F2α receptors cooperatively modulate signaling in vascular smooth muscle cells. The Journal of Biological Chemistry. 290: 3137-48. PMID 25512374 DOI: 10.1074/Jbc.M114.631119 |
0.407 |
|
| 2014 |
Galan A, Dergham P, Escoll P, de-la-Hera A, D'Onofrio PM, Magharious MM, Koeberle PD, Frade JM, Saragovi HU. Neuronal injury external to the retina rapidly activates retinal glia, followed by elevation of markers for cell cycle re-entry and death in retinal ganglion cells. Plos One. 9: e101349. PMID 24983470 DOI: 10.1371/Journal.Pone.0101349 |
0.311 |
|
| 2014 |
Brahimi F, Ko E, Malakhov A, Burgess K, Saragovi HU. Combinatorial assembly of small molecules into bivalent antagonists of TrkC or TrkA receptors Plos One. 9. PMID 24603864 DOI: 10.1371/Journal.Pone.0089617 |
0.543 |
|
| 2012 |
Ettinger K, Lecht S, Arien-Zakay H, Cohen G, Aga-Mizrachi S, Yanay N, Saragovi HU, Nedev H, Marcinkiewicz C, Nevo Y, Lazarovici P. Nerve growth factor stimulation of ERK1/2 phosphorylation requires both p75NTR and α9β1 integrin and confers myoprotection towards ischemia in C2C12 skeletal muscle cell model. Cellular Signalling. 24: 2378-88. PMID 22960610 DOI: 10.1016/J.Cellsig.2012.08.008 |
0.422 |
|
| 2012 |
Tong W, Sprules T, Gehring K, Saragovi HU. Rational design of peptide ligands against a glycolipid by NMR studies. Methods in Molecular Biology (Clifton, N.J.). 928: 39-52. PMID 22956132 DOI: 10.1007/978-1-62703-008-3_4 |
0.627 |
|
| 2011 |
Jain P, Li R, Lama T, Saragovi HU, Cumberlidge G, Meerovitch K. An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye. Experimental Eye Research. 93: 503-12. PMID 21726552 DOI: 10.1016/J.Exer.2011.06.014 |
0.307 |
|
| 2011 |
Bai Y, Sivori D, Woo SB, Neet KE, Lerner SF, Saragovi HU. During glaucoma, alpha2-macroglobulin accumulates in aqueous humor and binds to nerve growth factor, neutralizing neuroprotection. Investigative Ophthalmology & Visual Science. 52: 5260-5. PMID 21642630 DOI: 10.1167/Iovs.10-6691 |
0.378 |
|
| 2011 |
Aboulkassim T, Tong XK, Tse YC, Wong TP, Woo SB, Neet KE, Brahimi F, Hamel E, Saragovi HU. Ligand-dependent TrkA activity in brain differentially affects spatial learning and long-term memory. Molecular Pharmacology. 80: 498-508. PMID 21616921 DOI: 10.1124/Mol.111.071332 |
0.329 |
|
| 2010 |
Bai Y, Dergham P, Nedev H, Xu J, Galan A, Rivera JC, ZhiHua S, Mehta HM, Woo SB, Sarunic MV, Neet KE, Saragovi HU. Chronic and acute models of retinal neurodegeneration TrkA activity are neuroprotective whereas p75NTR activity is neurotoxic through a paracrine mechanism. The Journal of Biological Chemistry. 285: 39392-400. PMID 20943663 DOI: 10.1074/Jbc.M110.147801 |
0.45 |
|
| 2010 |
Brahimi F, Liu J, Malakhov A, Chowdhury S, Purisima EO, Ivanisevic L, Caron A, Burgess K, Saragovi HU. A monovalent agonist of TrkA tyrosine kinase receptors can be converted into a bivalent antagonist. Biochimica Et Biophysica Acta. 1800: 1018-26. PMID 20600627 DOI: 10.1016/J.Bbagen.2010.06.007 |
0.547 |
|
| 2010 |
Goupil E, Tassy D, Bourguet C, Quiniou C, Wisehart V, Pétrin D, Le Gouill C, Devost D, Zingg HH, Bouvier M, Saragovi HU, Chemtob S, Lubell WD, Claing A, Hébert TE, et al. A novel biased allosteric compound inhibitor of parturition selectively impedes the prostaglandin F2alpha-mediated Rho/ROCK signaling pathway. The Journal of Biological Chemistry. 285: 25624-36. PMID 20551320 DOI: 10.1074/Jbc.M110.115196 |
0.309 |
|
| 2010 |
Liu J, Brahimi F, Saragovi HU, Burgess K. Bivalent diketopiperazine-based tropomysin receptor kinase C (TrkC) antagonists. Journal of Medicinal Chemistry. 53: 5044-8. PMID 20540510 DOI: 10.1021/Jm100148D |
0.506 |
|
| 2010 |
Bai Y, Xu J, Brahimi F, Zhuo Y, Sarunic MV, Saragovi HU. An agonistic TrkB mAb causes sustained TrkB activation, delays RGC death, and protects the retinal structure in optic nerve axotomy and in glaucoma. Investigative Ophthalmology & Visual Science. 51: 4722-31. PMID 20357199 DOI: 10.1167/Iovs.09-5032 |
0.39 |
|
| 2010 |
Tong W, Gagnon M, Sprules T, Gilbert M, Chowdhury S, Meerovitch K, Hansford K, Purisima EO, Blankenship JW, Cheung NK, Gehring K, Lubell WD, Saragovi HU. Small-molecule ligands of GD2 ganglioside, designed from NMR studies, exhibit induced-fit binding and bioactivity. Chemistry & Biology. 17: 183-94. PMID 20189108 DOI: 10.1016/J.Chembiol.2010.01.012 |
0.631 |
|
| 2010 |
Guillemard V, Ivanisevic L, Garcia AG, Scholten V, Lazo OM, Bronfman FC, Saragovi HU. An agonistic mAb directed to the TrkC receptor juxtamembrane region defines a trophic hot spot and interactions with p75 coreceptors. Developmental Neurobiology. 70: 150-64. PMID 19953569 DOI: 10.1002/Dneu.20776 |
0.48 |
|
| 2010 |
Bassili M, Birman E, Schor NF, Saragovi HU. Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo. Cancer Chemotherapy and Pharmacology. 65: 1047-56. PMID 19701634 DOI: 10.1007/S00280-009-1110-X |
0.482 |
|
| 2009 |
Chen D, Brahimi F, Angell Y, Li YC, Moscowicz J, Saragovi HU, Burgess K. Bivalent peptidomimetic ligands of TrkC are biased agonists and selectively induce neuritogenesis or potentiate neurotrophin-3 trophic signals. Acs Chemical Biology. 4: 769-81. PMID 19735123 DOI: 10.1021/Cb9001415 |
0.521 |
|
| 2009 |
Brahimi F, Malakhov A, Lee HB, Pattarawarapan M, Ivanisevic L, Burgess K, Saragovi HU. A peptidomimetic of NT-3 acts as a TrkC antagonist. Peptides. 30: 1833-9. PMID 19647025 DOI: 10.1016/J.Peptides.2009.07.015 |
0.522 |
|
| 2009 |
Rihakova L, Quiniou C, Hamdan FF, Kaul R, Brault S, Hou X, Lahaie I, Sapieha P, Hamel D, Shao Z, Gobeil F, Hardy P, Joyal JS, Nedev H, Duhamel F, ... Saragovi HU, et al. VRQ397 (CRAVKY): a novel noncompetitive V2 receptor antagonist. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 297: R1009-18. PMID 19641130 DOI: 10.1152/ajpregu.90766.2008 |
0.385 |
|
| 2009 |
Lebrun-Julien F, Morquette B, Douillette A, Saragovi HU, Di Polo A. Inhibition of p75(NTR) in glia potentiates TrkA-mediated survival of injured retinal ganglion cells. Molecular and Cellular Neurosciences. 40: 410-20. PMID 19146958 DOI: 10.1016/J.Mcn.2008.12.005 |
0.464 |
|
| 2008 |
Kojic LD, Wiseman SM, Ghaidi F, Joshi B, Nedev H, Saragovi HU, Nabi IR. Raft-dependent endocytosis of autocrine motility factor/phosphoglucose isomerase: a potential drug delivery route for tumor cells. Plos One. 3: e3597. PMID 18974847 DOI: 10.1371/Journal.Pone.0003597 |
0.371 |
|
| 2008 |
Shi Z, Rudzinski M, Meerovitch K, Lebrun-Julien F, Birman E, Di Polo A, Saragovi HU. Alpha2-macroglobulin is a mediator of retinal ganglion cell death in glaucoma. The Journal of Biological Chemistry. 283: 29156-65. PMID 18701465 DOI: 10.1074/Jbc.M802365200 |
0.317 |
|
| 2008 |
Angell Y, Chen D, Brahimi F, Saragovi HU, Burgess K. A combinatorial method for solution-phase synthesis of labeled bivalent beta-turn mimics. Journal of the American Chemical Society. 130: 556-65. PMID 18088119 DOI: 10.1021/Ja074717Z |
0.342 |
|
| 2007 |
Shi Z, Birman E, Saragovi HU. Neurotrophic rationale in glaucoma: a TrkA agonist, but not NGF or a p75 antagonist, protects retinal ganglion cells in vivo. Developmental Neurobiology. 67: 884-94. PMID 17506493 DOI: 10.1002/Dneu.20360 |
0.495 |
|
| 2007 |
Ivanisevic L, Zheng W, Woo SB, Neet KE, Saragovi HU. TrkA receptor "hot spots" for binding of NT-3 as a heterologous ligand. The Journal of Biological Chemistry. 282: 16754-63. PMID 17439940 DOI: 10.1074/Jbc.M701996200 |
0.504 |
|
| 2006 |
Peleshok J, Saragovi HU. Functional mimetics of neurotrophins and their receptors. Biochemical Society Transactions. 34: 612-7. PMID 16856874 DOI: 10.1042/BST0340612 |
0.43 |
|
| 2006 |
Esteban PF, Yoon HY, Becker J, Dorsey SG, Caprari P, Palko ME, Coppola V, Saragovi HU, Randazzo PA, Tessarollo L. A kinase-deficient TrkC receptor isoform activates Arf6-Rac1 signaling through the scaffold protein tamalin. The Journal of Cell Biology. 173: 291-9. PMID 16636148 DOI: 10.1083/Jcb.200512013 |
0.501 |
|
| 2006 |
Ivanisevic L, Saragovi HU. The Neurotrophins Handbook of Biologically Active Peptides. 1407-1413. DOI: 10.1016/B978-012369442-3/50199-9 |
0.411 |
|
| 2005 |
Zaccaro MC, Lee HB, Pattarawarapan M, Xia Z, Caron A, L'Heureux PJ, Bengio Y, Burgess K, Saragovi HU. Selective small molecule peptidomimetic ligands of TrkC and TrkA receptors afford discrete or complete neurotrophic activities. Chemistry & Biology. 12: 1015-28. PMID 16183026 DOI: 10.1016/J.Chembiol.2005.06.015 |
0.558 |
|
| 2005 |
Thomas MS, Zhang W, Jordan PM, Saragovi HU, Taglialatela G. Signaling pathways mediating a selective induction of nitric oxide synthase II by tumor necrosis factor alpha in nerve growth factor-responsive cells. Journal of Neuroinflammation. 2: 19. PMID 16144552 DOI: 10.1186/1742-2094-2-19 |
0.379 |
|
| 2005 |
Tyurina YY, Nylander KD, Mirnics ZK, Portugal C, Yan C, Zaccaro C, Saragovi HU, Kagan VE, Schor NF. The intracellular domain of p75NTR as a determinant of cellular reducing potential and response to oxidant stress. Aging Cell. 4: 187-96. PMID 16026333 DOI: 10.1111/J.1474-9726.2005.00160.X |
0.41 |
|
| 2005 |
Mirnics ZK, Yan C, Portugal C, Kim TW, Saragovi HU, Sisodia SS, Mirnics K, Schor NF. P75 neurotrophin receptor regulates expression of neural cell adhesion molecule 1. Neurobiology of Disease. 20: 969-85. PMID 16006137 DOI: 10.1016/J.Nbd.2005.06.004 |
0.434 |
|
| 2005 |
Guillemard V, Nedev HN, Berezov A, Murali R, Saragovi HU. HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand. Dna and Cell Biology. 24: 350-8. PMID 15941387 DOI: 10.1089/Dna.2005.24.351 |
0.5 |
|
| 2005 |
Li S, Saragovi HU, Nedev H, Zhao C, Racine RJ, Fahnestock M. Differential actions of nerve growth factor receptors TrkA and p75NTR in a rat model of epileptogenesis. Molecular and Cellular Neurosciences. 29: 162-72. PMID 15911341 DOI: 10.1016/J.Mcn.2005.02.007 |
0.498 |
|
| 2004 |
Counts SE, Nadeem M, Wuu J, Ginsberg SD, Saragovi HU, Mufson EJ. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Annals of Neurology. 56: 520-31. PMID 15455399 DOI: 10.1002/Ana.20233 |
0.319 |
|
| 2004 |
Bruno MA, Clarke PB, Seltzer A, Quirion R, Burgess K, Cuello AC, Saragovi HU. Long-lasting rescue of age-associated deficits in cognition and the CNS cholinergic phenotype by a partial agonist peptidomimetic ligand of TrkA. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 8009-18. PMID 15371501 DOI: 10.1523/Jneurosci.1508-04.2004 |
0.465 |
|
| 2004 |
Guillemard V, Saragovi HU. Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity Oncogene. 23: 3613-3621. PMID 15034547 DOI: 10.1038/Sj.Onc.1207463 |
0.36 |
|
| 2004 |
Lee HB, Zaccaro MC, Pattarawarapan M, Roy S, Saragovi HU, Burgess K. Syntheses and activities of new C10 beta-turn peptidomimetics. The Journal of Organic Chemistry. 69: 701-13. PMID 14750794 DOI: 10.1021/Jo034167X |
0.399 |
|
| 2004 |
Rudzinski M, Wong TP, Saragovi HU. Changes in retinal expression of neurotrophins and neurotrophin receptors induced by ocular hypertension. Journal of Neurobiology. 58: 341-54. PMID 14750147 DOI: 10.1002/Neu.10293 |
0.431 |
|
| 2003 |
Ivanisevic L, Banerjee K, Saragovi HU. Differential cross-regulation of TrkA and TrkC tyrosine kinase receptors with p75. Oncogene. 22: 5677-85. PMID 12944916 DOI: 10.1038/Sj.Onc.1206864 |
0.552 |
|
| 2003 |
Pattarawarapan M, Reyes S, Xia Z, Zaccaro MC, Saragovi HU, Burgess K. Selective formation of homo- and heterobivalent peptidomimetics. Journal of Medicinal Chemistry. 46: 3565-7. PMID 12904060 DOI: 10.1021/Jm034103E |
0.331 |
|
| 2003 |
Taheri M, Saragovi HU, Stanners CP. The adhesion and differentiation-inhibitory activities of the immunoglobulin superfamily member, carcinoembryonic antigen, can be independently blocked. The Journal of Biological Chemistry. 278: 14632-9. PMID 12571231 DOI: 10.1074/Jbc.M212500200 |
0.362 |
|
| 2002 |
Yan C, Liang Y, Nylander KD, Wong J, Rudavsky RM, Saragovi HU, Schor NF. p75-nerve growth factor as an antiapoptotic complex: independence versus cooperativity in protection from enediyne chemotherapeutic agents. Molecular Pharmacology. 61: 710-9. PMID 11901208 DOI: 10.1124/Mol.61.4.710 |
0.54 |
|
| 2001 |
Zaccaro MC, Ivanisevic L, Perez P, Meakin SO, Saragovi HU. p75 Co-receptors regulate ligand-dependent and ligand-independent Trk receptor activation, in part by altering Trk docking subdomains. The Journal of Biological Chemistry. 276: 31023-9. PMID 11425862 DOI: 10.1074/Jbc.M104630200 |
0.562 |
|
| 2000 |
Beglova N, Maliartchouk S, Ekiel I, Zaccaro MC, Saragovi HU, Gehring K. Design and solution structure of functional peptide mimetics of nerve growth factor. Journal of Medicinal Chemistry. 43: 3530-40. PMID 11000007 DOI: 10.1021/Jm990441X |
0.759 |
|
| 2000 |
la Sala A, Corinti S, Federici M, Saragovi HU, Girolomoni G. Ligand activation of nerve growth factor receptor TrkA protects monocytes from apoptosis. Journal of Leukocyte Biology. 68: 104-10. PMID 10914496 DOI: 10.1189/Jlb.68.1.104 |
0.456 |
|
| 2000 |
Maliartchouk S, Debeir T, Beglova N, Cuello AC, Gehring K, Saragovi HU. Genuine monovalent ligands of TrkA nerve growth factor receptors reveal a novel pharmacological mechanism of action. The Journal of Biological Chemistry. 275: 9946-56. PMID 10744669 DOI: 10.1074/Jbc.275.14.9946 |
0.785 |
|
| 2000 |
Saragovi HU, Gehring K. Development of pharmacological agents for targeting neurotrophins and their receptors. Trends in Pharmacological Sciences. 21: 93-8. PMID 10689362 DOI: 10.1016/S0165-6147(99)01444-3 |
0.442 |
|
| 2000 |
Maliartchouk S, Feng Y, Ivanisevic L, Debeir T, Cuello AC, Burgess K, Saragovi HU. A designed peptidomimetic agonistic ligand of TrkA nerve growth factor receptors. Molecular Pharmacology. 57: 385-91. PMID 10648649 |
0.787 |
|
| 1999 |
Saragovi HU, Rebai N, Di Guglielmo GM, Macleod R, Sheng J, Rubin DH, Greene MI. A G1 cell cycle arrest induced by ligands of the reovirus type 3 receptor is secondary to inactivation of p21ras and mitogen-activated protein kinase. Dna and Cell Biology. 18: 763-70. PMID 10541435 DOI: 10.1089/104454999314908 |
0.471 |
|
| 1999 |
Debeir T, Saragovi HU, Cuello AC. A nerve growth factor mimetic TrkA antagonist causes withdrawal of cortical cholinergic boutons in the adult rat. Proceedings of the National Academy of Sciences of the United States of America. 96: 4067-72. PMID 10097164 DOI: 10.1073/pnas.96.7.4067 |
0.325 |
|
| 1999 |
Saragovi HU, Burgess K. Small molecule and protein-based neurotrophic ligands: Agonists and antagonists as therapeutic agents Expert Opinion On Therapeutic Patents. 9: 737-751. DOI: 10.1517/13543776.9.6.737 |
0.496 |
|
| 1998 |
Saragovi HU, Zheng W, Maliartchouk S, DiGugliemo GM, Mawal YR, Kamen A, Woo SB, Cuello AC, Debeir T, Neet KE. A TrkA-selective, fast internalizing nerve growth factor-antibody complex induces trophic but not neuritogenic signals. The Journal of Biological Chemistry. 273: 34933-40. PMID 9857023 DOI: 10.1074/Jbc.273.52.34933 |
0.776 |
|
| 1998 |
Saragovi HU, Bhandoola A, Moreau JL, Lavine N, Gagnon M, Lemercier MM, Théze J. Functional and physical association of a cell surface phospholipid and interleukin-2 receptor p55(alpha) subunits. Biochimica Et Biophysica Acta. 1414: 51-64. PMID 9804890 DOI: 10.1016/S0005-2736(98)00152-7 |
0.368 |
|
| 1998 |
Debeir T, Saragovi HU, Cuello AC. TrkA antagonists decrease NGF-induced ChAT activity in vitro and modulate cholinergic synaptic number in vivo. Journal of Physiology, Paris. 92: 205-8. PMID 9789809 DOI: 10.1016/S0928-4257(98)80011-9 |
0.427 |
|
| 1998 |
Roux E, Robaire B, Saragovi HU. A cell cycle regulating receptor is localized on cell surface and in nuclei of mitotically and meiotically dividing cells. Dna and Cell Biology. 17: 239-47. PMID 9539104 |
0.343 |
|
| 1997 |
Maliartchouk S, Saragovi HU. Optimal nerve growth factor trophic signals mediated by synergy of TrkA and p75 receptor-specific ligands. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 17: 6031-7. PMID 9236214 DOI: 10.1523/Jneurosci.17-16-06031.1997 |
0.781 |
|
| 1997 |
Shanmugam K, Featherstone MS, Saragovi HU. Residues flanking the HOX YPWM motif contribute to cooperative interactions with PBX. The Journal of Biological Chemistry. 272: 19081-7. PMID 9228093 DOI: 10.1074/Jbc.272.30.19081 |
0.302 |
|
| 1997 |
Mufson EJ, Lavine N, Jaffar S, Kordower JH, Quirion R, Saragovi HU. Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. Experimental Neurology. 146: 91-103. PMID 9225742 DOI: 10.1006/Exnr.1997.6504 |
0.39 |
|
| 1996 |
LeSauteur L, Cheung NK, Lisbona R, Saragovi HU. Small molecule nerve growth factor analogs image receptors in vivo. Nature Biotechnology. 14: 1120-2. PMID 9631063 DOI: 10.1038/nbt0996-1120 |
0.417 |
|
| 1996 |
LeSauteur L, Maliartchouk S, Le Jeune H, Quirion R, Saragovi HU. Potent human p140-TrkA agonists derived from an anti-receptor monoclonal antibody. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 16: 1308-16. PMID 8778282 DOI: 10.1523/Jneurosci.16-04-01308.1996 |
0.783 |
|
| 1996 |
Rebai N, Almazan G, Wei L, Greene MI, Saragovi HU. A p65/p95 neural surface receptor is expressed at the S-G2 phase of the cell cycle and defines distinct populations. The European Journal of Neuroscience. 8: 273-81. PMID 8714698 DOI: 10.1111/J.1460-9568.1996.Tb01211.X |
0.477 |
|
| 1995 |
LeSauteur L, Wei L, Gibbs BF, Saragovi HU. Small peptide mimics of nerve growth factor bind TrkA receptors and affect biological responses. The Journal of Biological Chemistry. 270: 6564-9. PMID 7896793 DOI: 10.1074/Jbc.270.12.6564 |
0.54 |
|
| 1995 |
Saragovi HU, Bhandoola A, Lemercier MM, Akbar GK, Greene MI. A receptor that subserves reovirus binding can inhibit lymphocyte proliferation triggered by mitogenic signals. Dna and Cell Biology. 14: 653-64. PMID 7646812 DOI: 10.1089/Dna.1995.14.653 |
0.485 |
|
| 1993 |
Sauvé GJ, Saragovi HU, Greene MI. Reovirus receptors. Advances in Virus Research. 42: 325-41. PMID 8430522 |
0.304 |
|
| 1993 |
Reed JC, Torigoe T, Turner BC, Merida I, Gaulton G, Saragovi HU, Rapp UR, Taichman R. Protooncogene-encoded protein kinases in interleukin-2 signal transduction. Seminars in Immunology. 5: 327-36. PMID 8260649 DOI: 10.1006/Smim.1993.1039 |
0.322 |
|
| 1992 |
Reed JC, Tanaka S, Cuddy M, Cho D, Smith J, Kallen R, Saragovi HU, Torigoe T. A strategy for generating monoclonal antibodies against recombinant baculovirus-produced proteins: application to the Bcl-2 oncoprotein. Analytical Biochemistry. 205: 70-6. PMID 1443560 DOI: 10.1016/0003-2697(92)90580-Z |
0.302 |
|
| 1992 |
Saragovi HU, Greene MI, Chrusciel RA, Kahn M. Loops and secondary structure mimetics: development and applications in basic science and rational drug design. Bio/Technology (Nature Publishing Company). 10: 773-8. PMID 1368266 DOI: 10.1038/Nbt0792-773 |
0.303 |
|
| 1991 |
Saragovi HU, Fitzpatrick D, Raktabutr A, Nakanishi H, Kahn M, Greene MI. Design and synthesis of a mimetic from an antibody complementarity-determining region. Science (New York, N.Y.). 253: 792-5. PMID 1876837 DOI: 10.1126/SCIENCE.1876837 |
0.332 |
|
| Show low-probability matches. |